Impact of etanercept on the costs of @entity309 ( XXXX ): results from a French observational study.

@entity2874 @entity1 @entity309 @entity7634
INTRODUCTION: Economical impact of @entity309 ( @entity309 ) has been widely modified thanks to @entity2874 inhibitors. Our study aims to estimate the impact etanercept prescription, in term of health resources consumption, within a regional cohort of French @entity309 @entity1 . METHODS: The study included 148 @entity309 @entity1 , with a mean follow-up duration of 343 days before and after etanercept initiation. Data were anonymously collected from ERASME database of French Health Insurance in Midi-Pyr  n  es region. A @entity1 -by- @entity1 microcosting approach was performed. RESULTS: The average annual cost per @entity1 , attributable to @entity309 , was 2.8 times higher after treatment by etanercept than before (15,148.57 @entity7634 versus 5248.95 @entity7634 ). We observed a rise in pharmaceutical costs, from 11.7% of direct medical costs before to 69.7% after etanercept initiation (120.12 @entity7634 versus 9995.23 @entity7634 ). We observed a small decrease particularly for NSAIDs (142.14 @entity7634 versus 102.21 @entity7634 ) and physiotherapy (286.40 @entity7634 versus 138.77 @entity7634 ). Attributable act costs and indirect costs did not differ before and after etanercept initiation. DISCUSSION: In this short-term study, initiation of etanercept in @entity309 @entity1 did not come along with a decrease of consumption of health resources. Long-term studies are needed to reveal a potential economical advantage as a consequence of the clinical, structural and functional efficacy of anti- @entity2874 .
